A Phase 3 interventional study of Rimegepant and Placebo in Acute Migraine, sponsored by Pfizer. Completed at 90 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 3, and was the 8th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 339 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,648 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 7th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2020, is one of 18 in phase 3, and was the 16th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
Biohaven Pharmaceuticals, Inc. is the agent for BioShin Limited, the sponsor of the studies in China and Korea.
Inclusion Criteria:
Subject has at least 1 year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition, Beta version including the following:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One 75mg oral disintegration tablet
Drug: Rimegepant
Matching placebo
Drug: Placebo
One 75mg orally disintegrating tablet
Matching placebo
Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (no pain) were considered to have freedom from pain. Exact 95 percent (%) confidence interval (CI) was based on Clopper-Pearson method.
Time frame: 2 hours post-dose
Percentage of Participants Who Had Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose
MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 2 hours post-dose
Percentage of Participants With Pain Relief at 2 Hours Post-dose
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants who reported a pain level of moderate or severe at baseline and then reported a pain level of none or mild at 2 hours post-dose, were considered to have pain relief. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 2 hours post-dose
Percentage of Participants Who Functioned Normally at 2 Hours Post-dose
Participants rated the level of disability they perceived as a result of their migraine in performing normal actions using following level of severity: normal function, mild impairment, severe impairment, or required bedrest. This outcome measure was analyzed only among those participants who reported any impairment at baseline. Percentage of participants with a response of "normal function" at the 2 hours post-dose were reported in this outcome measure.
Time frame: 2 hours post-dose
Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose
Percentage of participants who used rescue medications within 24 hours of administration of study drug were reported in this outcome measure. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 24 hours post-dose
Percentage of Participants Who Sustained Pain Freedom From 2 to 24 Hours Post-dose
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 2 to 24 hours post-dose
Percentage of Participants Who Sustained Pain Freedom From 2 to 48 Hours Post-dose
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 2 to 48 hours post-dose
Percentage of Participants Who Had Freedom From Pain at 15, 30, 45, 60 and 90 Minutes Post-dose
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Percentage of participants who reported a pain level of moderate or severe just before taking study treatment and then reported a pain level of none at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 15, 30, 45, 60 and 90 minutes post-dose
Percentage of Participants Who Had Freedom From MBS at 15, 30, 45, 60 and 90 Minutes Post-dose
MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 15, 30, 45, 60 and 90 minutes post-dose
Percentage of Participants With Pain Relapse
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. This outcome measure was analyzed only in those participants who were pain free at 2 hours post-dose. Percentage of participants who were pain free at 2 hours post-dose and then had a migraine of any pain severity (score 2 or 3 on the 4-point scale) within 48 hours after administration of study drug were considered to have pain relapse. Exact 95% CI was based on Clopper-Pearson method.
Time frame: 2 Hours to 48 Hours Post-dose
Overall, 1648 participants were enrolled and screened. A total of 217 participants were screen failures. Only 1431 participants were randomized. Out of 1431 participants, only 1342 participants were treated.
| Milestone | Rimegepant 75 Milligram (mg) | Placebo |
|---|---|---|
| Started | 716 | 715 |
| Treated | 668 | 674 |
| Completed | 709 | 704 |
| Not completed | 7 | 11 |
| Withdrew: Other | 0 | 5 |
| Withdrew: Covid-19 | 0 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Withdrew: Participant anxious to go to their hometown and withdrew from study | 1 | 0 |
| Withdrew: Participant refused to come to the hospital | 1 | 0 |
| Withdrew: Participant refused the visit | 1 | 0 |
| Withdrew: Participant quit early because of business trip | 1 | 0 |
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (no pain) were considered to have freedom from pain. Exact 95 percent (%) confidence interval (CI) was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose | 19.8 (16.9 to 23.1) | 10.7 (8.5 to 13.3) |
MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Had Freedom From Most Bothersome Symptoms (MBS) at 2 Hours Post-dose | 50.5 (46.6 to 54.3) | 35.8 (32.1 to 39.5) |
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants who reported a pain level of moderate or severe at baseline and then reported a pain level of none or mild at 2 hours post-dose, were considered to have pain relief. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants With Pain Relief at 2 Hours Post-dose | 66.5 (62.8 to 70.1) | 48.5 (44.7 to 52.4) |
Participants rated the level of disability they perceived as a result of their migraine in performing normal actions using following level of severity: normal function, mild impairment, severe impairment, or required bedrest. This outcome measure was analyzed only among those participants who reported any impairment at baseline. Percentage of participants with a response of "normal function" at the 2 hours post-dose were reported in this outcome measure.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Functioned Normally at 2 Hours Post-dose | 40.7 (36.6 to 45.0) | 23.8 (20.3 to 27.6) |
Percentage of participants who used rescue medications within 24 hours of administration of study drug were reported in this outcome measure. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Used Rescue Medication Within 24 Hours Post-dose | 8.4 (6.4 to 10.8) | 20.0 (17.1 to 23.3) |
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 24 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Sustained Pain Freedom From 2 to 24 Hours Post-dose | 15.6 (12.9 to 18.6) | 7.9 (5.9 to 10.2) |
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Participants with score of 0 (with no pain) through 2 to 48 hours post-dose were considered to have sustained pain freedom. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants Who Sustained Pain Freedom From 2 to 48 Hours Post-dose | 14.9 (12.2 to 17.8) | 7.1 (5.3 to 9.3) |
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. Percentage of participants who reported a pain level of moderate or severe just before taking study treatment and then reported a pain level of none at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| 15 minutes post-dose | 0.8 (0.2 to 1.7) | 1.5 (0.7 to 2.7) |
| 30 minutes post-dose | 1.1 (0.4 to 2.2) | 1.0 (0.4 to 2.1) |
| 45 minutes post-dose | 3.3 (2.1 to 5.0) | 2.2 (1.3 to 3.6) |
| 60 minutes post-dose | 6.8 (5.0 to 8.9) | 4.5 (3.0 to 6.3) |
| 90 minutes post-dose | 12.3 (9.9 to 15.1) | 7.1 (5.3 to 9.3) |
MBS included nausea, phonophobia or photophobia. MBS were measured using a binary scale as 0= absent, 1= present. Participants who had score of 0 (MBS absent) were considered to have freedom from MBS at the specified timepoints. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| 15 minutes post-dose | 10.2 (8.0 to 12.8) | 11.1 (8.9 to 13.7) |
| 30 minutes post-dose | 16.8 (14.1 to 19.9) | 14.8 (12.2 to 17.7) |
| 45 minutes post-dose | 24.2 (21.0 to 27.6) | 19.9 (16.9 to 23.1) |
| 60 minutes post-dose | 31.1 (27.6 to 34.7) | 24.8 (21.6 to 28.2) |
| 90 minutes post-dose | 41.4 (37.7 to 45.3) | 31.8 (28.2 to 35.4) |
Pain was measured on a 4-point Likert scale, with following scores: 0= none, 1= mild, 2= moderate, 3= severe. This outcome measure was analyzed only in those participants who were pain free at 2 hours post-dose. Percentage of participants who were pain free at 2 hours post-dose and then had a migraine of any pain severity (score 2 or 3 on the 4-point scale) within 48 hours after administration of study drug were considered to have pain relapse. Exact 95% CI was based on Clopper-Pearson method.
| Percentage of participants | Rimegepant 75 mg | Placebo |
|---|---|---|
| Percentage of Participants With Pain Relapse | 25.0 (17.9 to 33.3) | 33.3 (22.7 to 45.4) |
Collected over Up to 7 days post-dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rimegepant 75 mg | 0/668 (0%) | 1/668 (0.1%) | 92/668 (13.8%) |
| Placebo | 0/674 (0%) | 2/674 (0.3%) | 94/674 (13.9%) |
| Event | Rimegepant 75 mg | Placebo |
|---|---|---|
| InfectionInfections and infestations | 1/668 | 0/674 |
| HaemoperitoneumGastrointestinal disorders | 0/668 | 1/674 |
| Decreased embryo viabilityInjury, poisoning and procedural complications | 0/668 | 1/674 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 0/668 | 1/674 |
| Event | Rimegepant 75 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 7/668 | 18/674 |
| Protein urine presentInvestigations | 8/668 | 7/674 |
| Urinary tract infectionInfections and infestations | 5/668 | 8/674 |
| Blood creatine phosphokinase increasedInvestigations | 5/668 | 3/674 |
| AnaemiaBlood and lymphatic system disorders | 2/668 | 5/674 |
| ProteinuriaRenal and urinary disorders | 4/668 | 1/674 |
| PhotophobiaEye disorders | 4/668 | 3/674 |
| VomitingGastrointestinal disorders | 1/668 | 4/674 |
| Upper respiratory tract infectionInfections and infestations | 3/668 | 4/674 |
| Blood urine presentInvestigations | 3/668 | 2/674 |
Baseline analysis population included all treated participants (all enrolled participants who took either of the study drug).
| Age, Continuous(Years) | Rimegepant 75 mg | Placebo | Total |
|---|---|---|---|
| Mean | 37.8 ± 10.13 | 37.7 ± 10.70 | 37.8 ± 10.42 |
| Sex: Female, Male(Participants) | Rimegepant 75 mg | Placebo | Total |
|---|---|---|---|
| Female | 526 | 563 | 1089 |
| Male | 142 | 111 | 253 |
| Race and Ethnicity Not Collected(Participants) | Rimegepant 75 mg | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2020 to primary completion in Nov 2021, 13 months.
Results were first posted in Dec 2023, 2 years after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 13 months is below that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant